Abstract
We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse-transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons (HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (P =.30) or CD4 cell counts (P =.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.
Publication types
-
Controlled Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acyclovir* / administration & dosage
-
Acyclovir* / pharmacology
-
Acyclovir* / therapeutic use
-
Adult
-
Antibodies, Viral / blood
-
Antiviral Agents* / administration & dosage
-
Antiviral Agents* / pharmacology
-
Antiviral Agents* / therapeutic use
-
CD4 Lymphocyte Count
-
Female
-
HIV Infections / complications
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV Reverse Transcriptase / genetics
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
Herpes Genitalis / complications
-
Herpes Genitalis / drug therapy*
-
Herpes Genitalis / epidemiology
-
Herpes Genitalis / virology
-
Herpesvirus 2, Human / drug effects*
-
Herpesvirus 2, Human / immunology
-
Humans
-
Male
-
RNA, Viral / blood
-
Treatment Outcome
-
Viral Load
-
Young Adult
Substances
-
Antibodies, Viral
-
Antiviral Agents
-
RNA, Viral
-
reverse transcriptase, Human immunodeficiency virus 1
-
HIV Reverse Transcriptase
-
Acyclovir